Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Remogliflozin etabonate (GSK189075)
Remogliflozin etabonate · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Hydrochlorothiazide (HCTZ) | DRUG | - |
| Remogliflozin etabonate (GSK189075) | DRUG | - |
| Furosemide | DRUG | - |
Inclusion Criteria: * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range...
Remogliflozin etabonate is an investigational small molecule developed by GSK plc for type 2 diabetes mellitus. It is a Phase 1 clinical candidate and has been studied in a completed Phase 1 trial in the United States. It is not approved for marketing.
Remogliflozin etabonate targets SLC5A2, also known as the sodium-glucose cotransporter 2. It acts as an inhibitor of this transporter. By inhibiting SLC5A2, the drug reduces renal glucose reabsorption, which is the intended mechanism for lowering blood glucose in type 2 diabetes mellitus.
Remogliflozin etabonate is being developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program for this investigational agent in type 2 diabetes mellitus.
Remogliflozin etabonate is in Phase 1 clinical development. It has completed one Phase 1 trial and has no active trials. It is investigational and has not been approved by the FDA for any indication.
Remogliflozin etabonate has been studied in one completed Phase 1 trial, NCT00671424, titled A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide. The trial enrolled 48 participants in the United States and included male healthy volunteers aged 18 years and older.
Yes, remogliflozin etabonate is also known as GSK189075. The two names refer to the same investigational compound developed by GSK plc for type 2 diabetes mellitus. The alternative designation GSK189075 appears in the title of its completed Phase 1 trial, NCT00671424.